Compare fluocinolone and dexamethasone implants for resistant eye swelling
Part of Eyes & vision, Hormones & metabolism clinical trials.
This trial looks at which long-acting steroid implant works better for diabetic macular swelling that did not improve enough with past treatments. It may help patients by testing a treatment option aimed at improving vision when other eye injections have not worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can give informed consent and you’re an adult
- You have diabetic macular swelling in one or both eyes that’s still present after years of treatment
- Your vision test result is limited (BCVA of 80 letters or less on the ETDRS scale)
- You were treated before: at least one steroid (dexamethasone) injection more than 5 months ago and at least one anti-VEGF injection more than 3 months ago
- Your eye lens situation matches the study: you are pseudophakic (received cataract lens surgery more than 6 months ago)
- Your current eye and health conditions must allow follow-up and make steroid implants safe (for example, no pregnancy, no serious eye infections, and controlled blood sugar)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
This early-phase trial tests a new implant (EC-104) that goes inside the eye to treat diabetic macular edema (DME), a condition that causes blurry vision from fluid buildup. The implant slowly releases medicine over time, and the study will see if it is safe and helpful for people with DME.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This phase 3 trial tests a new long-acting injection (EYP-1901) against a standard one (aflibercept) for people with diabetic macular edema. Both treatments are given as eye injections, and the goal is to see if the new drug works as well and may require fewer injections.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This study tests whether a medication called dapagliflozin, which is usually used for diabetes and heart failure, can help reduce swelling in the retina (diabetic macular edema) and improve vision. It is for people with type 2 diabetes who are already taking insulin and metformin.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.